Related Experiment Videos
[Central dopaminergic D1 agonists and treatment of Parkinson disease]
C Soubrouillard1, C Lombardo, O Rascol
1Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques et Laboratoire de Pharmacologie Médicale et Clinique, CHU Timone, Marseille, France.
Therapie
|September 12, 1998
Abstract:
Many theories about dopaminergic function in Parkinson's disease are based upon the effects of the D2 receptor. Standard treatments mostly involve dopaminergic D2 agonists. However, the recent development of dopaminergic D1 agonists should help to clarify the role of the D1 receptor in the treatment of Parkinson's disease. The authors review the physiopathological, behavioural and therapeutic data on D1 agonists administered in animal models and in patients.